The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?

@article{DHaens2011TheLP,
  title={The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?},
  author={Geert R D'Haens and Remo Panaccione and Peter D. R. Higgins and S{\'e}verine Vermeire and Miquel Angel Gassull and Yehuda Chowers and Stephen Hanauer and Hans H. Herfarth and Daniel W. Hommes and Michael A Kamm and Robert L{\"o}fberg and A Quary and Bruce E. Sands and Ajit Sood and G Watermayer and Bret A. Lashner and Marc L{\'e}mann and Scott Eric Plevy and Walter Reinisch and Stefan Schreiber and Corey A Siegel and Stephen R. Targan and M Watanabe and Brian G. Feagan and William J Sandborn and J F Colombel and Simon P L Travis},
  journal={The American Journal of Gastroenterology},
  year={2011},
  volume={106},
  pages={199-212}
}
The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but other… Expand
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety
TLDR
The immunogenicity of biological therapy is complex: all agents are potentially immunogenic and this can be reduced by combination with immunomodulators, so the balance of risk and benefit must be judged for individual patients. Expand
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Pregnancy and Pediatrics
TLDR
Anti-tumor necrosis factor therapy in pregnancy is considered to be low risk and compatible with use during conception in men and women and during pregnancy in at least the first two trimesters, but safety data for adalimumab (ADA) are awaited. Expand
Biological Treatment of Crohn’s Disease
TLDR
Randomized, controlled studies focusing on trough levels and antibodies towards the biological agent in routine clinical situations may add important pieces to the puzzle for a more rational treatment algorithm of CD patients. Expand
Biologic Therapy in Inflammatory Bowel Disease—A Gastrointestinal Perspective
TLDR
Improvement of the patient's symptoms used to be the goal of therapy, this has shifted since the availability of anti-TNF therapy to mucosal healing as standard of care, and as monitoring of drug levels and antibodies becomes more available, it will improve safety and efficacy of these agents. Expand
Predictors of primary response to biologic treatment (anti-TNF, vedolizumab and ustekinumab) in patients with inflammatory bowel disease: from basic science to clinical practice.
TLDR
No single marker fulfils all criteria for being an appropriate prognostic indicator of response to any biologic treatment in IBD, and the availability of useful predictive markers seems to be even lower for vedolizumab. Expand
Biologic Therapy for Crohn’s Disease: Infliximab
TLDR
In the treatment of CD with infliximab, additional consideration should be given to the findings that significantly higher response rates were observed in patients who had a C-reactive protein greater 5 mg/L, and lower response rates have been observed in Patients with serum albumin concentrations 30 kg/M2. Expand
Treatment Algorithms for Crohn’s Disease
TLDR
Therapy algorithms are given as a guide through different CD scenarios to support the physician’s decision making and with the advantage of good safety profiles over TNF-inhibitors, these drugs will be more frequently used in the near future, also as first-line biologicals, compared to TNFs. Expand
Infliximab to treat Crohn’s disease: an update
TLDR
An update on existing evidence for the use of IFX in CD is provided, taking into account the safety profile in clinical practice and special situations such as pregnancy, and clinical factors at diagnosis may predict poor outcome in CD. Expand
Conventional medical management of inflammatory bowel disease.
TLDR
This review provides algorithms with a time-structured approach for guidance of therapy for management of inflammatory bowel diseases and shows how drug type, timing, and context must be optimized to manage individual patients effectively. Expand
se of biosimilars in inflammatory bowel disease : Statements of the talian Group for Inflammatory Bowel Disease
The introduction of biological therapies, particularly anti-TNF agents, has revolutionized the management of inflammatory bowel disease in those cases which are refractory to conventional treatment;Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 205 REFERENCES
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety
TLDR
The immunogenicity of biological therapy is complex: all agents are potentially immunogenic and this can be reduced by combination with immunomodulators, so the balance of risk and benefit must be judged for individual patients. Expand
Clinical experience with infliximab therapy in 100 patients with Crohn's disease
TLDR
The authors' clinical response rates mirror the efficacy reported in the controlled trials for active and fistulous disease and steroid-sparing efficacy was seen in 40% of steroid-dependent patients. Expand
Is Anti-TNF Therapy Always Prohibited in Patients with Inflammatory Bowel Disease and Previous Malignancy ?
  • 2009
INTRODUCTION The name tumor necrosis factor (TNF) implies, logically enough, an action to necrose tumor cells. Treatment to inhibit TNF (anti-TNF therapy with adalimumab, certolizumab pegol, orExpand
Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
  • A. Orlando, E. Colombo, +20 authors M. Cottone
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2005
TLDR
In Crohn's disease infliximab is effective in luminal refractory and in fistulising disease, whereas perianal fistulas predicted a better response than other type of fistulas. Expand
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease
TLDR
In this large cohort of infliximab-treated CD patients, young age, Crohn's colitis, and concomitant immunosuppressive treatment were identified as independent variables favoring short-term response to inflixIMab. Expand
Immunomodulators and “On Demand” Therapy with Infliximab in Crohn's Disease: Clinical Experience with 400 Infusions
TLDR
Concomitant use of immunomodulators with infliximab in patients with Crohn's disease did not improve patient response to several parameters measured, including clinical response rate, dose reduction of prednisone, fistula response, and mean intervals between inflixIMab infusions. Expand
Certolizumab pegol for the treatment of Crohn’s disease
  • S. Schreiber
  • Medicine
  • Therapeutic advances in gastroenterology
  • 2011
TLDR
Treatment with certolizumab pegol has been shown to improve function and quality of life in patients with CD, and insights into the potential mechanisms by which this agent effects a response in CD suggest that this agent may have the potential to slow or even modify disease progression. Expand
A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism
TLDR
A positive clinical response to infliximab was associated with a higher CRP level before treatment in the population of Crohn disease patients, but there was no relevant association with -308 TNF gene polymorphism. Expand
Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review
TLDR
There is no clear evidence that ATIs have an impact on efficacy or safety, nor a need to measure or prevent them in clinical practice, and circulating drug concentration may be a more relevant measure of immunogenicity. Expand
Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials
TLDR
Budesonide 6 mg/day is effective for prolonging time to relapse and for significantly reducing rates of relapse at 3 and 6 months but not 12 months in patients with CD in medically induced remission. Expand
...
1
2
3
4
5
...